- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.11. | The Latest Analyst Ratings For Femasys | 4 | Benzinga.com | ||
| 26.11. | Femasys Inc.: Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed Infertility Treatment | 80 | GlobeNewswire (Europe) | ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office... ► Artikel lesen | |
| 12.11. | Femasys GAAP EPS of -$0.24, revenue of $554.91M | 1 | Seeking Alpha | ||
| 12.11. | Femasys Inc.: Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update | 72 | GlobeNewswire (Europe) | ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office... ► Artikel lesen | |
| 01.11. | Femasys secures new patent for FemBloc birth control | 2 | Investing.com | ||
| FEMASYS Aktie jetzt für 0€ handeln | |||||
| 01.11. | Femasys Inc.: Femasys Announces Issued U.S. Patent Covering FemBloc Device for Female Permanent Birth Control | 1 | GlobeNewswire (USA) | ||
| 30.10. | Femasys Inc.: Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed | 1 | GlobeNewswire (USA) | ||
| 29.10. | FEMASYS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 10.10. | Femasys Inc.: Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program | 1 | GlobeNewswire (USA) | ||
| 02.10. | Femasys Inc.: Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments | 1 | GlobeNewswire (USA) | ||
| 18.09. | Femasys Inc.: Femasys Announces Infertility Clinic Customers from Coast to Coast | 4 | GlobeNewswire (USA) | ||
| 12.09. | H.C. Wainwright maintains Buy rating on Femasys on secureing strategic Spain distribution | 1 | Investing.com | ||
| 12.09. | Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | 1 | Benzinga.com | ||
| 11.09. | Femasys secures partnerships for commercialization of Femaseed and FemVue | 1 | Seeking Alpha | ||
| 11.09. | Femasys Inc.: Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market | 1 | GlobeNewswire (USA) | ||
| 10.09. | Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device | 1 | Zacks | ||
| 09.09. | FDA clears Femasys' FemChec diagnostic device | 1 | MassDevice | ||
| 09.09. | Femasys Receives 510(k) Clearance From FDA To Market FemChec For Fallopian Tube Diagnosis | - | RTTNews | ||
| 09.09. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 09.09. | Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 506,80 | +0,06 % | Intuitive Surgical Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| ROKU | 75,73 | +0,03 % | Roku (NASDAQ:ROKU) Trading 0.2% Higher - Here's What Happened | ||
| ATOSSA THERAPEUTICS | 0,950 | -1,66 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density | 1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a Poster Spotlight Session During... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| EMEIS | 5,376 | +0,62 % | emeis announces €251m in disposals of real estate and operating assets since the beginning of October | Nearly €900 million in disposals completed since mid-2022 or secured to date Disposal of activities in Chile and the Czech Republic
Regulatory News:
emeis (Paris:EMEIS) today announced... ► Artikel lesen | |
| QUIDELORTHO | 42,000 | -2,33 % | Does QuidelOrtho Corporation (QDEL) Have Healthy Long-Term Growth Prospects? | ||
| CENTENE | 57,31 | -1,02 % | Hedge Fund and Insider Trading News: Chris Hohn, Seth Klarman, Warren Buffett, Third Point, Palliser Capital, Centene Corp (CNC), Salesforce Inc (CRM), and More | ||
| TEMPEST THERAPEUTICS | 0,815 | +0,25 % | Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics... ► Artikel lesen | |
| VERU | 0,611 | -2,24 % | Veru (NASDAQ:VERU) Receives "Buy" Rating from HC Wainwright | ||
| FULGENT GENETICS | 17,600 | -1,68 % | Fulgent Reports Third Quarter 2024 Financial Results | EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic... ► Artikel lesen | |
| NANO-X IMAGING | 7,015 | -0,78 % | Nano-X Imaging LTD.: Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication | Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications, in addition to its previously cleared indication... ► Artikel lesen | |
| LANTHEUS | 86,26 | -1,35 % | AKTIONÄR-Tipp Lantheus: Goldman rät zum Kauf | Wachstumssorgen um das radiopharmazeutische Diagnostik-Produkt Pylarify haben der Aktie von Lantheus zuletzt zugesetzt. Geht es nach den Analysten von Goldman Sachs, so sind diese Zweifel nicht gerechtfertigt.... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,900 | -4,61 % | Perspective Therapeutics, Inc.: Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society ... | [212Pb]VMT-a-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested (2.5 and 5.0 mCi)Eight of nine patients had durable control of disease.... ► Artikel lesen | |
| AMN HEALTHCARE SERVICES | 21,200 | +0,95 % | AMN Healthcare Services (NYSE:AMN) Reaches New 1-Year Low - Here's What Happened | ||
| BUTTERFLY NETWORK | 3,085 | +2,15 % | Butterfly Network (NYSE:BFLY) Shares Down 6.3% - What's Next? |
Das Unternehmen FEMASYS INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +3,27 % bei einem Aktienkurs von 1,105 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FEMASYS INC finden Sie auf Wallstreet Online.
